Responsiveness of infants to capsular polysaccharides: Implications for vaccine development

Reviews and Research in Medical Microbiology

Volumn 7, Issue 1, 1996, Pages 3-12

  Rijkers, Ger T ^a   Sanders, Elisabeth A M ^a   Breukels, Mijke A ^a   Zegers, Ben J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Capsular polysaccharides; Fe receptors; T cell independent antigens; Vaccine development

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; FC RECEPTOR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CHILD; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOREGULATION; INFANT; INFECTION PREVENTION; ONTOGENY; OTITIS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE;

EID: 0030025022     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199601000-00001     Document Type: Review

References (50)

1. Wald ER, Guerra, N, Byers, C. Upper respiratory tract infections in young children: duration of and frequency of complications. Pediatrics 1991; 87: 129-133.
2. Gray BM, Dillon HC. Clinical and epidemiological studies of pneumococcal infection in children. Pediatr Infect Dis 1986; 5: 201-207.
3. Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis 1981; 3: 246-253.
4. Austrian R. Otitis media. John Hopkins Med J 1977; 141: 104-111.
5. Thomas JD, Sideras P, Smith CIE, Vorechovsky I, Chapman V, Paul WE. A missense mutation in the X-linked agammaglobulinemia gene colocalizes with the mouse X-linked immunodeficiency gene. Science 1993; 261: 355-358.
6. Mosier DE, Subbarrao B. Thymus-independent antigens: complexity of B-lymphocyte activation revealed. Immunol Today 1982; 3: 217-222.
7. Amlot PL, Grennan D, Humphreys JH. Splenic dependence of the antibody response to thymus independent (TI-2) antigens. Eur J Immunol 1985; 15: 508-512.
8. Harding CV, Roof, RW, Allen PW, Unanue ER. Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. Proc Natl Acad Sci USA 1991; 88: 2740-2744.
9. Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74: 857-865.
10. Insel RA, Kittelberger A, Anderson P. Isoelectric focusing of human antibody to the Haemophilus influenzae b capsular polysaccharide: restricted and identical spectrotypes in adults. J Immunol 1985; 135: 2810-2816.
11. Herrmann DJ, Hamilton RG, Barington T et al. Quantitation of human IgG subclass antibodies to Haemophilus influenzae type b capsular polysaccharide. J. Immunol Meth 1992; 148: 101-114.
12. L families. J Immunol 1989; 143: 293-298.
13. Braley-Mullen H. Regulatory role of T cells in IgG antibody formation and immune memory to type III pneumococcal polysaccharide. J Immunol 1974; 113: 1909-1920.
14. Baker PJ. T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications. J Infect Dis 1992; 165 (suppl 1): S44-S48.
15. Griffioen AW, Toebes EAH, Rijkers GT, Claas FHJ, Dateman G, Zegers BJM. The amplifier role of T cells in the human in vitro B cell reponse to type 4 pneumococcal polysaccharide. Immunol Lett 1992; 32: 265-272.
16. Griffioen AW, Rijkers GT, Toebes EAH, Zegers BJM. The human in vitro anti-type 4 pneumococcal polysaccharide antibody response is regulated by suppressor T cells. Scand J Immunol 1991; 34: 229-236.
17. Munoz JL, Insel RA. In vitro human antibody production to the Haemophilus influenzae type b capsular polysaccharide. J Immunol 1987; 139 206-212.
18. Baker PJ, Amsbaugh DF, Stashak PW, Caldes G, Prescott B. Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells. Rev Infect Dis 1981; 3: 332-341.
19. Mongini PKA, Stein KE, Paul WE. T cell regulation of IgG subclass antibody production in response to T-dependent antigens. J Exp Med 1981; 153: 1-12.
20. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148: 131-137.
21. Cowan MJ, Ammann AJ, Wara DW et al. Pneumococcal polysaccharide immunization in infants and children. Pediatrics 1978; 62: 721-727.
22. Gross S, Blaiss MS, Herrod HG. Role of the immunoglobulin subclasses and specific determinations in the evaluation of recurrent infection in children. J Pediatrics 1992; 121: 516-522.
23. Austrian R. Pneumococcal polysaccharide vaccines. Rev Infect Dis 1989; 11 (suppl 3): S598-S602.
24. Rijkers GT, Dollekamp EG, Zegers BJM. The in vitro response to pneumococcal polysaccharides in adults and neonates. Scand J Immunol 1987; 25: 447-452.
25. Rijkers GT, Dollekamp I, Zegers BJM. 8-Mercaptoguanosine overcomes unresponsiveness of human neonatal B cells to polysaccharide antigens. J Immunol 1988; 141: 2313-2316.
26. Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992; 13: 431-433.
27. Cooper NR, Moore MD, Nemerow GR. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Ann Rev Immunol 1988; 6: 85-113.
28. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989; 46: 183-219.
29. Bohnsack JF, Cooper NR. CR2 ligands modulate human B cell activation. J Immunol 1988; 141: 2569-2576.
30. Matsumoto AK, Kopicky Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 1991; 173: 55-64.
31. Fine DP. Pneumococcal type-associated variability in alternate complement pathway activation. Infect Immun 1975; 12: 772-778.
32. Winkelstein JA, Bocchini JA, Jr, Schiffmann G. The role of capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. J Immunol 1976; 116: 367-378.
33. Griffioen AW, Rijkers GT, Janssens-Korpela P, Zegers BJM. Pneumococcal polysaccharides complexed wtih C3d bind to human B lymphocytes via complement receptor type 2. Infect Immun 1991; 59: 1839-1845.
34. Griffioen AW, Toebes EAM, Zegers BJM, Rijkers GT. Role of the CR2 in the human adult and neonatal in vitro antibody response to type 4 pneumococcal polysaccharide. Cell Immunol 1992; 143: 11-22.
35. Timens WA, Bols A, Uiterwijk-Rozeboom T, Poppema S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 1989; 143: 3200-3206.
36. Mäkelä PH, Takala AH, Peltola H, Eskola J. Epidemiology of invasive Haemophilus influenzae type b disease. J Infect Dis 1992; 165 (suppl): S2-S6.
37. Granoff DM, Holmes SJ. G2m(23) immunoglobulin allotype and immunity to Haemophilus influenzae. J Infect Dis 1992; 165 (suppl 1): S66-S69.
38. van de Winkel JGJ, Capel PJA. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunology Today 1993; 14: 215-221.
39. Sanders EAM, Feldman RG, Voorhorst-Ogink MM et el. Human IgG Fc receptor IIA (CD32) polymorphism and IgG-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63: 73-81.
40. Sanders EAM, van de Winkel JGJ, Rijkers GT et al. Fcγ Receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994; 170: 854-861.
41. Borgono JM, McLean AA, Vella PP et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978; 157: 148-154.
42. Goebel WF, Avery OT. Chemo-immunological studies on conjugated carbohydrate proteins. II. Immunological specificity of synthetic sugar proteins. J Exp Med 1929; 50: 533-550.
43. Eskola J, Peltola H, Mäkelä P et al. Antibody levels achieved in infants by course of Haemophilus influenzae type b/diphtheria toxoid conjugate vaccine. Lancet 1985; i: 1184-1186.
44. Peeters CCAM, Tenbergen-Meekes A-M, Poolman JT, Zegers BJM, Rijkers GT. In vitro antibody response of human lymphocytes to the Haemophilus influenzae type b capsular polysaccharide. Springer Sem Immunopathol 1993; 15: 247-258.
45. Peeters CCAM, Tenbergen-Meekes A-M, Heijnen CJ, Poolman JT, Zegers BJM, Rijkers GT. In vitro activation of human T lymphocytes by Haemophilus influenzae type b. Scand J Immunol 1992; 35: 137-148.
46. Insel RA, Anderson PW. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J Exp Med 1986; 163: 262-269.
47. Robbins JB, Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 1990; 161: 821-832.
48. Eskola J, Käyhty H, Takala AK et al. A randomized prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381-1387.
49. Steinhoff MC, Edwards J, Keyserling H et al. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J 1994; 13: 368-372.
50. Giebink GS, Koskela M, Vella PP, Harris M, Le CT. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otits media. J Infect Dis 1993; 167: 347-355.